Terilyn Monroe Sells 46,300 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) insider Terilyn Monroe sold 46,300 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the sale, the insider directly owned 22,979 shares in the company, valued at approximately $3,794,292.48. This represents a 66.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Guardant Health Trading Down 1.5%

GH opened at $157.21 on Friday. Guardant Health, Inc. has a 1-year low of $53.40 and a 1-year high of $176.58. The stock has a market capitalization of $21.10 billion, a PE ratio of -45.05 and a beta of 1.60. The firm has a 50-day moving average price of $150.40 and a two-hundred day moving average price of $116.87.

Analyst Ratings Changes

GH has been the subject of a number of recent analyst reports. Sanford C. Bernstein upped their price objective on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, July 2nd. Morgan Stanley boosted their target price on Guardant Health from $175.00 to $185.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Canaccord Genuity Group upped their price target on Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Barclays increased their price target on shares of Guardant Health from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Finally, TD Cowen boosted their price objective on shares of Guardant Health from $200.00 to $210.00 and gave the company a “buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $183.78.

Hedge Funds Weigh In On Guardant Health

Several hedge funds have recently modified their holdings of GH. Jupiter Topco LLC acquired a new position in Guardant Health during the second quarter worth approximately $18,071,000. Kinetic Partners Management LP acquired a new stake in shares of Guardant Health in the second quarter valued at approximately $19,489,000. ABS Investment Management LLC acquired a new stake in shares of Guardant Health in the second quarter valued at approximately $345,069,000. Hsbc Holdings PLC bought a new position in shares of Guardant Health during the 2nd quarter worth approximately $15,910,000. Finally, EFG International AG bought a new position in shares of Guardant Health during the 2nd quarter worth approximately $60,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.